Back to results
US 2021/0340617 A1Published application
Endometriosis-associated genetic markers predict responsiveness to leuprolide acetate
AssigneeJuneau Biosciences, LLC
InventorsKenneth WARD, VeeAnn ARGYLE, Peeches CEDERHOLM, Rakesh CHETTIER
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of using genetic variants to select for an effective treatment of endometriosis, for example via a computer-implemented program to predict responsiveness of a subject to a selected treatment, and methods of diagnosing endometriosis or a symptom thereof.
Claims69
A method comprising:
- (a) detecting a presence of at least one genetic variant of Table 1 in a genetic material obtained from a subject, wherein the subject has endometriosis or is at risk of developing endometriosis;
- and
- (b) treating the subject for the endometriosis with a therapeutically effective amount of a treatment that comprises leuprolide acetate, a derivative thereof, a biosimilar thereof, or an interchangeable thereof.
A method comprising:
- (a) detecting a presence of at least one genetic variant of Table 2 in a genetic material obtained from a subject, wherein the subject has endometriosis or is at risk of developing endometriosis;
- and
- (b) treating the subject for the endometriosis with a therapeutically effective amount of a treatment that does not comprise leuprolide acetate.
A method comprising:
- detecting a presence of at least one genetic variant of Table 1 in a genetic material obtained from a subject, wherein the subject has endometriosis or is at risk of developing endometriosis, wherein the presence of the at least one genetic variant of Table 1 is indicative of a therapeutically effective response to a treatment for treating the endometriosis, and wherein the treatment comprises leuprolide acetate, a derivative thereof, a biosimilar thereof, or an interchangeable thereof.
A method comprising:
- detecting a presence of at least one genetic variant of Table 2 in a genetic material obtained from a subject, wherein the subject has endometriosis or is a risk of developing endometriosis, wherein the presence of the at least one genetic variant of Table 2 is indicative of a therapeutically effective response to a treatment for treating the endometriosis, wherein the treatment does not comprise leuprolide acetate.
Dependencies are inferred from the claim text.